Agile Therapeutics Announces Changes to its Board of Directors
22 4월 2020 - 9:00PM
Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s
healthcare company, today announced that the company has nominated
Sharon Barbari for election as a class III director to replace
Abhijeet Lele, a member of the company’s board of directors and the
board’s Lead Independent Director, who will not stand for
re-election and cease to be a director on June 9, 2020, the date of
the company’s Annual Meeting of Stockholders. In addition, William
McKee has informed the company that he will retire from the
company’s board of directors effective June 9, 2020. The company
plans to appoint Sandra Carson, M.D., FACOG as a class II director
to replace Mr. McKee when he retires.
“Sharon’s extensive pharmaceutical leadership
experience and expertise leading financial operations through
periods of growth will be a valuable contribution to our Board,”
said Al Altomari, President and Chief Executive Officer of Agile.
“We look forward to her insight and guidance as we continue our
development as a commercial company.”
Ms. Barbari has over 40 years of pharmaceutical
and biotechnology experience, having served in various senior
financial roles, including Chief Financial Officer, at several
companies during her career, including Cytokinetics, InterMune and
Gilead Sciences.
“We are looking forward to Dr. Carson joining
our Board in June. She has significant clinical and research
expertise in women’s health coupled with established clinical
experience as an OB/GYN physician and regulatory experience through
her membership on U.S. Food and Drug Administration’s advisory
committees,” continued Mr. Altomari. “With her extensive background
in women’s health, we believe Dr. Carson will offer valuable
insight and guidance on our clinical and regulatory strategies for
our pipeline.”
Dr. Carson is a Professor of Obstetrics,
Gynecology and Reproductive Sciences and Director, Reproductive
Endocrinology and Infertility at Yale University. Most recently,
she served as the Emeritus Vice President for Education at the
American College of Obstetricians & Gynecologists (ACOG) from
August 2018 to February 2019 and Vice President for Education from
March 2013 to August 2018.
Mr. Lele has served on the company’s board of
directors since 2010 and as the board’s lead independent director
since 2016. Mr. McKee joined the board of directors in 2014, just
before the company’s initial public offering, and has served as the
chair of the board’s audit committee since that time. The company’s
board of directors plans to appoint Seth H.Z. Fischer as the lead
independent director to replace Mr. Lele at the annual meeting of
stockholders on June 9, 2020.
“Abhijeet is our longest serving independent
director and joined the board over 10 years ago. He has provided
important strategic insights, guidance and support throughout his
long-standing tenure on Agile’s board and his service as our lead
independent director,” stated Mr. Altomari. “In addition, since
joining our board as we pursued our initial public offering, Bill
has provided expert guidance to our company, especially in the
areas of fiscal discipline and risk management, through his
chairmanship of the board’s audit committee. On behalf of the other
board members and Agile’s management team, I would like to thank
both Abhijeet and Bill for their service to the company.”
About Agile Therapeutics,
Inc.Agile Therapeutics is a women's healthcare company
dedicated to fulfilling the unmet health needs of today’s women.
Our product candidates are designed to provide women with
contraceptive options that offer freedom from taking a daily pill,
without committing to a longer-acting method. Our initial product,
Twirla®, (levonorgestrel and ethinyl estradiol) transdermal system
is a non-daily prescription contraceptive. Twirla is based on our
proprietary transdermal patch technology, called Skinfusion®, which
is designed to allow drug delivery through the skin. For more
information, please visit the company website at
www.agiletherapeutics.com. The Company may occasionally disseminate
material, nonpublic information on the Company’s website.
Follow Agile on LinkedIn and Twitter:
@AgileTher.
Forward-Looking Statement
Certain information contained in this press
release includes “forward-looking statements” within the meaning of
The Private Securities Litigation Reform Act of 1995, including
statements related to the future composition of our board of
directors. We may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “continue,” “anticipates,” “estimates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of the future
events or outcomes to identify these forward-looking statements.
Our forward-looking statements are based on current beliefs and
expectations of our management team that involve risks, potential
changes in circumstances, assumptions, and uncertainties. Any or
all of the forward-looking statements may turn out to be wrong or
be affected by inaccurate assumptions we might make or by known or
unknown risks and uncertainties as a result of various important
factors, including the uncertainties related to current market
conditions and the other risks set forth in our filings with the
U.S. Securities and Exchange Commission, including our Annual
Report on Form 10-K and our Quarterly Reports on Form 10-Q. For all
these reasons, actual results and developments could be materially
different from those expressed in or implied by our forward-looking
statements. You are cautioned not to place undue reliance on these
forward-looking statements, which are made only as of the date of
this press release. We undertake no obligation to publicly update
such forward-looking statements to reflect subsequent events or
circumstances.
Source: Agile Therapeutics
Contact: Investor Relations -- 609-683-1880
Agile Therapeutics (NASDAQ:AGRX)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Agile Therapeutics (NASDAQ:AGRX)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024